Ugandan HIV activists Barbara Kemigisa shows Antiretroviral (ARV) packagings and tablets in an art design encouraging people infected with HIV to use the ARVs and fight against stigmatisation during ...
The Government is to roll out clinical trials for long-acting injectable ARVs (cabotegravir) for teenagers and adolescents aged 12 to 24 by the end of this year, the executive director of the Joint ...
The first long-acting injectable treatments for HIV were recommended for marketing approval on October 16 by the European Medicines Agency (EMA). Instead of daily pills, patients would receive ...
Health CS Susan Nakhumicha and Bungoma Governor Ken Lusaka in one of the stands at Kibabii University during celebrations to mark World Aids Day. [Benjamin Sakwa, Standard] The investigating team ...
STAKEHOLDERS in the health sector have welcomed the introduction of the pre-exposure prophylaxis (PrEP) injectable drug saying it will boost the fight against HIV/Aids. National Aids Council chief ...
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year ...
A two-drug cocktail injected every month or two may be just as effective as a daily pill at keeping the AIDS virus under control, said a study Monday that promised relief for millions. At present ...
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi Limited as shareholders, announced that the US Food and Drug ...
A two-drug cocktail injected every month or two may be just as effective as a daily pill at keeping the AIDS virus under control, said a study on Monday that promised relief for millions. At present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback